A novel Chimeric Antigen Receptor (CAR) - strategy to target EGFRVIII-mutated glioblastoma cells via macrophages

BACKGROUND: Autologous chimeric antigen receptor (CAR) expressing T-Cells (CAR-T) have been efficiently used in hematological malignancies but their efficacy in solid tumors remains limited. CAR therapies via the use of macrophages, offer a promising avenue due to their unique ability to infiltrate tumors and to initiate phagocytosis. METHODS: and MEGF10 intracellular domain which enhances tethering and phagocytosis activity. RESULTS: CAR-Macs against the glioblastoma cell line has also been observed using video microscopy. ELISA and LDH assays performed in co-culture supernatants, showed an increase of IL-6 and LDH levels suggesting efficient cytotoxicity via CAR-Macs. Transcriptome analyses performed in purified CAR-Macs, revealed evidence of a molecular signature in favor of successful phagocytosis. CONCLUSIONS: .